Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. InSilico Medicine Cayman TopCo's Revenue for the
three
months ended in Dec. 2025 was $28.78 Mil. InSilico Medicine Cayman TopCo's average Accounts Receivable for the
three
months ended in Dec. 2025 was $13.45 Mil.
Hence, InSilico Medicine Cayman TopCo's Receivables Turnover for the
three
months ended in Dec. 2025 was 2.14.
InSilico Medicine Cayman TopCo (OTCPK:ISLMF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
InSilico Medicine Cayman TopCo Receivables Turnover Related Terms
InSilico Medicine Cayman TopCo Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo Receivables Turnover Chart
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo Receivables Turnover vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (ISLMF) has a Receivables Turnover of 2.14 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #1375 out of 2786 companies in the Software industry, placing it in the top 49.4%.
Is InSilico Medicine Cayman TopCo's Receivables Turnover too high?
InSilico Medicine Cayman TopCo's current Receivables Turnover is 2.14. The Software industry median Receivables Turnover is 6.04. InSilico Medicine Cayman TopCo's value of 2.14 is 64.6% below this industry median. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #1375 out of 2786 companies in the Software industry, which is above the industry midpoint. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Receivables Turnover compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #1375 out of 2786 companies for Receivables Turnover. This puts InSilico Medicine Cayman TopCo in the upper half of its industry. The industry median Receivables Turnover is 6.04. InSilico Medicine Cayman TopCo's value of 2.14 is 64.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Software company?
The median Receivables Turnover among Software companies is 6.04, based on 2,786 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InSilico Medicine Cayman TopCo's current Receivables Turnover of 2.14 is 64.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median Receivables Turnover is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current Receivables Turnover is 2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current Receivables Turnover of 2.14. The current Receivables Turnover is 2.14 and 64.6% below the Software industry median of 6.04. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current Receivables Turnover is 2.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score
Get the complete analysis for ISLMF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISLMF has been successfully added to your 
